The prospects of peace have been a positive fillip for stocks this week with oil prices down from recent highs, though our market did get…
Here are four ETF ideas for conservative yield-focused investors as the cash rate rises.
How should I play the takeover offer for Atlas Arteria? What do the major brokers think of Woodside? Can I sell my entitlements in the…
Michael Gable, Managing Director of Fairmont Equities, shares his view with you on Macquarie Group (MQG).
In this week’s Boom Doom Zoom, we get a question on how to get in on the SpaceX IPO, and cover everything from Tabcorp to…
Is it time to relook at the healthcare sector? Here are 5 healthcare stocks that could be on the way up. But if you don’t…
In a month where the US S&P 500 added 10.5%, the Aussie share market clawed higher in April to record a gain of just 2.2%.…
Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans regards ResMed (RMD) as a BUY.
Here are three stocks, two with world-leading proprietary software and one with a growing specialisation in providing its clients with the capability and capacity to…
For the week ending Friday 1 May 2026, FNArena recorded nine upgrades and 10 downgrades from the seven brokers monitored daily across ASX-listed companies.
Switzer TV aired its 4 May 2026 edition on the eve of the RBA’s May rate decision, with four expert guests joining Peter Switzer to…
Stocks were largely up on Wall Street for Friday’s trade, and it followed our local market snapping our worst run of outs — eight days…